Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Santen Licenses Anti-Endoglin Antibodies from TRACON to Develop Novel Treatments for Retinal Diseases
March 6, 2014
- Samsca Tops January “Mind Share” Ranking in HP Market
March 5, 2014
- Eylea Filed for Diabetic Macular Edema in Japan: Bayer HealthCare
March 5, 2014
- Takeda Extended 3.7 Billion Yen in CASE-J-Linked Grants to Kyoto Univ., 2 Entities; “No COI” Says Pres. Hasegawa
March 4, 2014
- Takeda Apologizes for Violating Promotion Code, Inappropriate Expressions in Ads
March 4, 2014
- DSP Transfers Marketing Rights for Inteban, Catlep, and Drenison to Teikoku Seiyaku
March 4, 2014
- Astellas Secures Exclusive Rights for Isavuconazole in US, Canada
March 4, 2014
- Dnavec, NCGM, Nippon Zenyaku to Codevelop Drug Discovery Tool for Anti-Obesity Treatment
March 3, 2014
- Takeda Files NDA for Promising Acid-Related Disease Drug in Japan
March 3, 2014
- Novartis Files for Approval of Exforge OD Tablets
March 3, 2014
- Takeda’s Next Leader Weber to Take Up COO Role on April 1
March 3, 2014
- Mizuho Projects 5% Upswing for FY2014 Operating Profit of 9 Major Japan Pharmas
February 28, 2014
- Nipro Opens Sales Subsidiary in Sweden
February 28, 2014
- Fujifilm Sets Up Chinese Subsidiary for Regenerative Medicine Business, Eyeing Provision of Epidermis Culturing Services by 2015
February 28, 2014
- All DPP-4 Inhibitors to Undergo Major Price Reductions Due to Market Expansion of Januvia/Glactiv; Re-pricing Could Affect SGLT-2 Inhibitors as Well
February 28, 2014
- 72 Drug Makers Provided 483 Billion Yen in Funding to Medical and Research Institutions in FY2012
February 27, 2014
- Quintiles to Increase Contract Sales Reps in Japan: Global Commercial Head Evangelista
February 26, 2014
- Shionogi Announces Reorganization to Boost R&D Capabilities
February 26, 2014
- Ranbaxy’s Toansa, Dewas Plants Voluntarily Suspend API Shipments Worldwide
February 26, 2014
- Takeda to Realign Japan Sales Team
February 25, 2014
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…